A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02
{{output}}
Purpose: This phase 2 trial investigated rucaparib (PARP inhibitor) in combination with nivolumab in patients with advanced BTC without progression after 4-6 months of first-line platinum-based chemotherapy. ... ...
